Compare INUV & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | NSRX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 25.8M |
| IPO Year | 1996 | N/A |
| Metric | INUV | NSRX |
|---|---|---|
| Price | $1.86 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $11.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 217.9K | 176.1K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $86,209,305.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.34 | $1.98 |
| 52 Week High | $6.27 | $9.99 |
| Indicator | INUV | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 36.03 |
| Support Level | $1.83 | $1.98 |
| Resistance Level | $1.99 | $5.20 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 13.73 | 40.85 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.